期刊
PROTEOMICS
卷 15, 期 19, 页码 3361-3369出版社
WILEY
DOI: 10.1002/pmic.201400142
关键词
Biomarkers; Biomedicine; Cerebrospinal fluid; Multiple sclerosis; Quantitative mass spectrometry; Secretogranin-1
资金
- National Program for Research in Functional Genomics (FUGE) - Norwegian Research Council
- Western Norway Regional Health Authority
- Leiv Eiriksson Mobility Program
- Meltzer Foundation
- Kristian Gerhard Jebsen Foundation
- Proteomics Platform of the Broad Institute of MIT
- Proteomics Platform of the Broad Institute of Harvard
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS with unknown cause. Proteins with different abundance in the cerebrospinal fluid (CSF) from relapsing-remitting MS (RRMS) patients and neurological controls could give novel insight to the MS pathogenesis and be used to improve diagnosis, predict prognosis and disease course, and guide in therapy decisions. We combined iTRAQ labeling and Orbitrap mass spectrometry to discover proteins with different CSF abundance between six RRMS patients and 18 neurological disease controls. From 777 quantified proteins seven were selected as biomarker candidates, namely chitinase-3-like protein 1, secretogranin-1 (Sg1), cerebellin-1, neuroserpin, cell surface glycoprotein MUC18, testican-2 and glutamate receptor 4. An independent sample set of 13 early-MS patients, 13 RRMS patients and 13 neurological controls was used in a multiple reaction monitoring verification study. We found the intracellular calcium binding protein Sg1 to be increased in early-MS patients compared to RRMS and neurological controls. Sg1 should be included in further studies to elucidate its role in the early phases of MS pathogenesis and its potential as a biomarker for this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据